Global Hereditary Angioedema Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431768
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Cipla, Inc.
  • CSL Behring Ltd.
  • iBio, Inc.
  • Merck & Co., Inc.
  • Other Notable Players
  • Pharming Group NV
  • MORE
Hereditary Angioedema Market - Growth, Future Prospects, Competitive Analysis, 2017 - 2025, the global hereditary angioedema market was valued at US$ 1,750.2 Mn in 2016, and is expected to reach US$ 3,689.4 Mn by 2025 expanding at a CAGR of 8.19% from 2017 to 2025.

Market Insights

Hereditary angioedema is a rare autosomal dominant disorder and has disease epidemiology of one individual per 10,000 - 50,000 without major sex or ethnic differences. Hereditary angioedema has resulted in tremendous humanistic burden on patients in terms of poor physical and mental health causing a major setback on education, career, work productivity and socioeconomic impediment. Introduction of disease specific treatment drugs in the past decade has improved patients’ quality of life and reduced the cost related to hospitalization.

In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option). Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising product pipeline, touted to offer better results than the existing treatment options. The drug in Phase III DX 2930 has received breakthrough therapy designation and orphan drug designation by the USFDA. Phase II drug BCX-7353 is an oral preparation to counteract the severe swelling attacks in the intestinal and airway tract.

In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of hereditary angioedema, increasing expenditure by the pharmaceutical giants in the research and development to counteract hereditary angioedema symptoms and existence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as increasing frequency of symptoms in patients suffering with hereditary angioedema requiring immediate medical intervention, increasing disposable incomes in these regions and supportive regulatory environment for hereditary angioedema drugs.

Key Market Movements:
  • Increasing incidences of underlying symptoms reflecting association with hereditary angioedema
  • Technological advancement has led to launch of novel drugs such as Berinert and Haegarda, which have better efficacy compared to the conventional drugs opted to subdue symptoms
  • Supportive regulatory environment for hereditary angioedema drugs
  • Affordable reimbursement scenario for the treatment of rare genetic diseases in the developed countries
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cipla, Inc.
  • CSL Behring Ltd.
  • iBio, Inc.
  • Merck & Co., Inc.
  • Other Notable Players
  • Pharming Group NV
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Hereditary Angioedema Market Portraiture
2.1.1. Global Hereditary Angioedema Market, by Drug Class, 2016
2.1.2. Global Hereditary Angioedema Market, by Geography, 2016

Chapter 3. Hereditary Angioedema: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Hereditary Angioedema Market, by Drug Class
4.3. C1 Esterase Inhibitors
4.3.1. Berinert
4.3.2. Haegarda
4.3.3. Cinryze
4.3.4. Ruconest
4.4. Kallikrien Inhibitor
4.4.1. Kalbitor
4.5. Selective Bradykinin B2 Receptor Antagonist
4.5.1. Firazyr
4.6. Others

Chapter 5. Global Hereditary Angioedema Market, by Product Drugs, 2015 - 2025 (US$ Mn)
5.1. Overview
5.2. Phase III Drug
5.2.1. DX-2930
5.3. Phase II Drug (Qualitative Information)
5.3.1. BCX-7353

Chapter 6. Global Hereditary Angioedema Market, by Geography, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. North America Hereditary Angioedema Market Analysis, 2015 - 2025
6.2.1. North America Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.2.2. North America Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Hereditary Angioedema Market Analysis, 2015 - 2025
6.3.1. Europe Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.3.2. Europe Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. France
6.3.2.4. Rest of Europe
6.4. Asia Pacific Hereditary Angioedema Market Analysis, 2015 - 2025
6.4.1. Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.4.2. Asia Pacific Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. India
6.4.2.4. Rest of APAC
6.5. Latin America Hereditary Angioedema Market Analysis, 2015 - 2025
6.5.1. Latin America Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.5.2. Latin America Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Hereditary Angioedema Market Analysis, 2015 - 2025
6.6.1. MEA Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.6.2. MEA Hereditary Angioedema Market, by Region, 2015 - 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. BioCryst Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Cipla, Inc.
7.3. CSL Behring Ltd.
7.4. Ionis Pharmaceuticals, Inc.
7.5. iBio, Inc.
7.6. Merck & Co., Inc.
7.7. Pharming Group NV
7.8. Sanofi N.V.
7.9. Shire plc.
7.10. Teva Pharmaceutical Industries, Ltd.
7.11. Other Notable Players

List of Figures
Fig. 1 Hereditary Angioedema: Market Segmentation
Fig. 2 Global Hereditary Angioedema Market Share, by Drug Class, 2016 (Value %)
Fig. 3 Global Hereditary Angioedema Market Share, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition, by Geography
Fig. 5 Market Competition Landscape, by Key Players, 2016
Fig. 6 Global C1 Esterase Inhibitors Market, 2015 - 2025 (US$ Mn)
Fig. 7 Global Berinert Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Haegarda Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Cinryze Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Ruconest Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Kalbitor Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global Firazyr Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Other Drug Class for Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 14 U.S. Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 15 Canada Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 16 U.K. Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 17 Germany Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 18 France Hereditary Angioedema Market, 2015-2025 (US$ Mn)
Fig. 19 Rest of Europe Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 20 Japan Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 21 China Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 22 India Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 23 Rest of Asia Pacific Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 24 Brazil Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 25 Mexico Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 26 Rest of Latin America Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 27 GCC Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)
Fig. 28 Rest of Middle East and Africa Hereditary Angioedema Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 2 Global Hereditary Angioedema Market, by Pipeline Drugs, 2015 - 2025 (US$ Mn)
Table 3 Global Hereditary Angioedema Market, by Geography, 2015 - 2025 (US$ Mn)
Table 4 North America Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 5 North America Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
Table 6 Europe Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 7 Europe Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
Table 8 Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 9 Asia Pacific Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
Table 10 Latin America Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 11 Latin America Hereditary Angioedema Market, by Country, 2015 - 2025 (US$ Mn)
Table 12 Middle East and Africa Hereditary Angioedema Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 13 Middle East and Africa Hereditary Angioedema Market, by Region, 2015 - 2025 (US$ Mn)
Table 14 BioCryst Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 15 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 16 CSL Behring Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 17 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 18 iBio, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 19 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 20 Pharming Group NV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 21 Sanofi N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 22 Shire plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • BioCryst Pharmaceuticals, Inc.
  • Cipla, Inc.
  • CSL Behring Ltd.
  • Ionis Pharmaceuticals, Inc.
  • iBio, Inc.
  • Merck & Co., Inc.
  • Pharming Group NV
  • Sanofi N.V.
  • Shire plc.
  • Teva Pharmaceutical Industries, Ltd.
  • Other Notable Players
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll